<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-10-32</article-id><article-id pub-id-type="pmid">19351416</article-id><article-id pub-id-type="doi">10.1186/1471-2350-10-32</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lack of association between <italic>PRNP </italic>1368 polymorphism and Alzheimer's disease or vascular dementia</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Jeong</surname><given-names>Byung-Hoon</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bhjeong@hallym.ac.kr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Lee</surname><given-names>Kyung-Hee</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>puremind72@empal.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Lee</surname><given-names>Yun-Jung</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jjung0301@hallym.ac.kr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Kim</surname><given-names>Yun Joong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yunkim@hallym.ac.kr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Choi</surname><given-names>Eun-Kyoung</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ekchoi@hallym.ac.kr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kim</surname><given-names>Young-Hoon</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>sml-yh@smlab.co.kr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Cho</surname><given-names>Young-Sook</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>yscho@smlab.co.kr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Carp</surname><given-names>Richard I</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Richard.carp@omr.state.ny.us</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Kim</surname><given-names>Yong-Sun</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yskim@hallym.ac.kr</email></contrib></contrib-group><aff id="I1"><label>1</label>Ilsong Institute of Life Science, Hallym University, 1605-4 Gwanyang-dong, Dongan-gu, Anyang, Gyeonggi-do 431-060, South Korea</aff><aff id="I2"><label>2</label>Samkwang Medical Laboratories, 9&#x02013;60, Yangjae-dong, Seocho-gu, Seoul 137&#x02013;887, South Korea</aff><aff id="I3"><label>3</label>New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>8</day><month>4</month><year>2009</year></pub-date><volume>10</volume><fpage>32</fpage><lpage>32</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/32"/><history><date date-type="received"><day>29</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>8</day><month>4</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Jeong et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Jeong et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Jeong Byung-Hoon bhjeong@hallym.ac.kr </dc:author><dc:title> Lack of association between PRNP 1368 polymorphism and Alzheimer's disease or vascular dementia </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 10(1): 32-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2009)10:1&#x0003c;32&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Polymorphisms of the prion protein gene (<italic>PRNP</italic>) at codons 129 and 219 play an important role in the susceptibility to Creutzfeldt-Jakob disease (CJD), and might be associated with other neurodegenerative disorders. Several recent reports indicate that polymorphisms outside the coding region of <italic>PRNP </italic>modulate the expression of prion protein and are associated with sporadic CJD, although other studies failed to show an association. These reports involved the polymorphism <italic>PRNP </italic>1368 which is located upstream from <italic>PRNP </italic>exon 1. In a case-controlled protocol, we assessed the possible association between the <italic>PRNP </italic>1368 polymorphism and either Alzheimer's disease (AD) or vascular dementia (VaD).</p></sec><sec sec-type="methods"><title>Methods</title><p>To investigate whether the <italic>PRNP </italic>1368 polymorphism is associated with the occurrence of AD or VaD in the Korean population, we compared the genotype, allele, and haplotype frequencies of the <italic>PRNP </italic>1368 polymorphism in 152 AD patients and 192 VaD patients with frequencies in 268 healthy Koreans.</p></sec><sec><title>Results and conclusion</title><p>Significant differences in genotype, allele and haplotype frequencies of <italic>PRNP </italic>1368 polymorphism were not observed between AD and normal controls. There were no significant differences in the genotype and allele frequencies of the <italic>PRNP </italic>1368 polymorphism between Korean VaD patients and normal controls. However, in the haplotype analysis, haplotype Ht5 was significantly over-represented in Korean VaD patients. This was the first genetic association study of a polymorphism outside the coding region of <italic>PRNP </italic>in relation to AD and VaD.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Alzheimer's disease (AD), the most common cause of dementia in the aged population, is associated with progressive memory deterioration and disordered cognitive function resulting from a loss of cholinergic transmission and characterized neuropathologically by the presence of neurofibrillary tangles and amyloid plaques in the brain and clinically by gradual loss of memory. These changes may result from destructive processes involving the disruption of microtubule assembly and synaptic loss. Further neuronal damage and disease progression are consequences of this damage. Although the processes involved in AD could be triggered by many environmental factors, genetic studies have shown that in some cases mutations and polymorphisms of particular genes can confer susceptibility to the degenerative process. Several genes associated with AD have been identified, including amyloid precursor protein gene (<italic>APP</italic>), presenilin-1 gene (<italic>PS1</italic>), presenilin-2 gene (<italic>PS2</italic>), and the apolipoprotein E gene (<italic>ApoE</italic>) [<xref ref-type="bibr" rid="B1">1</xref>]. AD and prion diseases, such as Creutzfeldt-Jakob disease (CJD), share a number of clinical, pathogenetic and pathological features. A structural hallmark of AD is amyloid-&#x003b2; peptide (A&#x003b2;) aggregates in extracellular amyloid deposits defined as senile plaques, while in CJD there is an accumulation of abnormal protease-resistant isoform (PrP<sup>res</sup>) in neurons and in extracellular amyloid-like aggregates. A&#x003b2;-positive senile plaques in AD brains commonly contain PrP<sup>C </sup>deposits [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>] and incidental A&#x003b2;-positive senile plaques in prion diseases such as CJD may also be positive for PrP<sup>C </sup>[<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Vascular dementia (VaD) is the second most common cause of dementia after AD. VaD is a clinical syndrome causing cognitive decline due to cerebrovascular lesions. Risk factors for VaD are age, sex, race, hypertension, smoking, diabetes mellitus, and hypercholesterolemia. However, there is no conclusive evidence for the association of genetic polymorphisms with VaD. VaD and prion diseases share some pathophysiological similarities, such as the occurrence of dementia.</p><p>Prion protein contains 253 amino acids encoded by prion protein gene (<italic>PRNP</italic>), located on chromosome 20p12.3 in humans. <italic>PRNP </italic>plays an important role in conferring susceptibility or resistance to prion disease. A number of mutations in the open reading frame (ORF) are linked to the familial form of prion diseases [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Polymorphisms at codons 129 or 219 of <italic>PRNP </italic>are susceptibility factors to sporadic CJD [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. In several European populations, an association between the <italic>PRNP </italic>codon 129 polymorphism and AD was reported [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. In contrast to these studies, other studies failed to detect a significant association between this polymorphism and AD [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>], and in Asian populations, no association between the <italic>PRNP </italic>codons 129/219 polymorphisms and AD was reported [<xref ref-type="bibr" rid="B19">19</xref>]. Recently, the polymorphism (<italic>PRNP </italic>1368) in an upstream of <italic>PRNP </italic>exon 1 was found to be associated with sporadic CJD in British and German populations [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>], but this association was not seen in Dutch and Korean populations [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. This polymorphism was studied in other diseases in addition to sporadic CJD. In a British population, there was no association of <italic>PRNP </italic>1368 polymorphism with frontotemporal lobar degeneration (FTLD) [<xref ref-type="bibr" rid="B24">24</xref>]. Although <italic>PRNP </italic>1368 polymorphism has been studied in sporadic CJD and FTLD patients, a case-controlled association study between the <italic>PRNP </italic>1368 polymorphism and either AD or VaD has not been reported thus far.</p><p>In the present study, the purpose was to investigate the genotype and allele frequency of a polymorphism outside the coding region of <italic>PRNP </italic>in Korean AD and VaD patients and to determine the correlation between this polymorphism and the incidence of AD and VaD in the Korean population.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Analysis included 152 Korean patients with AD (51 male and 101 female; mean age at disease onset 73.48 &#x000b1; 8.00 years), which were diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria [<xref ref-type="bibr" rid="B25">25</xref>] with minor modification specifying the gradual onset and progression of memory loss with a duration of at least 12 months. None of these patients reported family history of AD. All AD patients were gathered from Chunchon, South Korea and were examined in the Department of Neurology, Chunchon Sacred Heart Hospital. General medical and neurological examinations, neuropsychological testing, and computed topography scans were performed to exclude other forms of dementia. Blood samples were collected from 152 AD patients between May 2000 and June 2005. One hundred ninety two Korean patients with VaD (100 male and 92 female; mean age: 71.95 &#x000b1; 8.92 years) were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [<xref ref-type="bibr" rid="B26">26</xref>] and National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria [<xref ref-type="bibr" rid="B27">27</xref>] after clinical examination and neuropsychological testing, including mini-mental state examination (MMSE). VaD patients were gathered from Anyang, South Korea and were examined in the Department of Neurology, Hallym University Hospital. Blood samples were collected from 192 VaD patients between May 2000 and June 2008. The control subjects were 268 unrelated individuals (118 male and 150 female; mean age 71.17 &#x000b1; 8.68 years) matched for age and ethnic background to AD patients and VaD patients (Table <xref ref-type="table" rid="T1">1</xref>). All control subjects were volunteers recruited from routine health checkups at the Chunchon Sacred Heart Hospital. None of them presented symptoms of dementia or any movement disorders. Absence of dementia was determined by considering past history and Korean MMSE criterion (score of &#x0003e;24). Blood samples were collected from 268 healthy Korean volunteers between May 2000 and June 2005. The study was approved by the Ethical Committee of Chunchon Sacred Heart Hospital and an informed consent was given by all subjects or their caregivers. All blood samples were frozen at -70&#x000b0;C prior to analysis.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of AD and VaD patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Control</td><td align="center">AD</td><td align="center">P value<sup>a</sup></td><td align="center">VaD</td><td align="center">P value<sup>a</sup></td></tr></thead><tbody><tr><td align="left">Number of subjects</td><td align="center">268</td><td align="center">152</td><td></td><td align="center">192</td><td></td></tr><tr><td align="left">Gender</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Male, n (%)</td><td align="center">118 (44.0%)</td><td align="center">51 (33.55%)</td><td align="center">0.014</td><td align="center">100 (52.1%)</td><td align="center">0.090</td></tr><tr><td align="left">&#x02003;Female, n (%)</td><td align="center">150 (56.0%)</td><td align="center">101 (66.45%)</td><td></td><td align="center">92 (47.9%)</td><td></td></tr><tr><td align="left">Mean age at disease onset (years &#x000b1; SD)</td><td align="center">-</td><td align="center">73.48 &#x000b1; 8.00</td><td align="center">0.006</td><td align="center">71.95 &#x000b1; 8.92</td><td align="center">0.348</td></tr><tr><td align="left">Mean age at blood collection (years &#x000b1; SD)</td><td align="center">71.17 &#x000b1; 8.68</td><td align="center">-</td><td></td><td align="center">-</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Based on the difference between controls and AD or VaD patients</p></table-wrap-foot></table-wrap></sec><sec><title>Genotyping</title><p>Genomic DNA was extracted from 200 &#x003bc;l blood using the QIAamp DNA blood mini kit (Qiagen, USA) following the supplier's instructions. Polymerase chain reaction (PCR) was performed with J-1 (GAGAAAACCTTGCGTCAGCA) and J-2 (AAGGTGCAGAAAAGATGGGC) primers. These primers were designed to amplify a 586 bp product in an upstream region of <italic>PRNP </italic>exon 1. The PCR reagents contained 50 pmole of each primer, 5 &#x003bc;l of 10 &#x000d7; <italic>Taq </italic>DNA polymerase buffer, 1.5 mM MgCl<sub>2</sub>, 0.2 mM of each dNTP mixtures, and 2.5 units of <italic>Taq </italic>DNA polymerase (Promega, USA). The PCR conditions were 94&#x000b0;C for 2 min to denature, and 35 cycles of 94&#x000b0;C for 45 sec, 56&#x000b0;C for 45 sec, and 72&#x000b0;C for 1 min 30 sec, and then 1 cycle of 72&#x000b0;C for 10 min to extend the reaction. The Perkin-Elmer Cetus DNA thermal cycler (Pekin-Elmer, USA) was used. Restriction cleavage sites were searched using Webcutter, ver. 2.0 (Carolina Biological Supply Co., USA). A 20 &#x003bc;l aliquot of purified PCR mixture was digested at 37&#x000b0;C for 1 h with 5 units of <italic>Pvu II </italic>(Invitrogen, USA). Restriction products were separated on a 1.5% agarose gel and visualized with ethidium bromide staining under UV light. The purification of PCR products for sequencing was done using a QIAquick gel extraction kit (Qiagen, USA). The PCR products were directly sequenced on an ABI 377 automatic sequencer using a <italic>Taq </italic>dideoxy terminator cycle sequencing kit (ABI, USA) and the same primers as indicated earlier in the standard conditions.</p></sec><sec><title>Statistical analyses</title><p>A &#x003c7;<sup>2 </sup>test was used to determine whether the <italic>PRNP </italic>1368 polymorphism was in Hardy-Weinberg equilibrium (HWE) in the Korean population. Odds ratios (OR) with 95% confidence interval (CI) and <italic>P</italic>-values were calculated by using the codominant model, controlling for age and sex as covariates. Differences in age of populations were analyzed using Student's <italic>t</italic>-test, and sex differences by using &#x003c7;<sup>2 </sup>test. Haplotypes and their frequencies were inferred using the algorithm developed by Stephens et al. [<xref ref-type="bibr" rid="B28">28</xref>]. Fisher's exact test was used to analyze differences in haplotype frequency between the normal population and patients with AD and VaD. The statistical powers were calculated using Statistical Power Calculator <ext-link ext-link-type="uri" xlink:href="http://www.dssresearch.com/toolkit/spcalc/power_p2.asp"/>.</p></sec></sec><sec><title>Results</title><p>The genotype frequencies at <italic>PRNP </italic>1368 were in HWE in Korean control group (<italic>P </italic>= 0.742) and AD group (<italic>P </italic>= 0.226), not in VaD group (P = 0.025) (data not shown). To examine a correlation between the <italic>PRNP </italic>1368 polymorphism and susceptibility of AD in Koreans, we examined the genotype and allele frequencies of this polymorphism in 152 Korean AD patients and in 268 healthy controls. No significant difference between Korean AD patients and controls was found in genotype or allele frequency of the <italic>PRNP </italic>1368 polymorphism (Table <xref ref-type="table" rid="T2">2</xref>). This result suggests that the <italic>PRNP </italic>1368 polymorphism does not increase susceptibility to AD. When our data set was stratified by gender, there was no significant association between this polymorphism and AD (data not shown).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Genotype and allele frequencies of the PRNP 1368 polymorphism in the normal population, AD patients, and VaD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Control<break/>(n = 268)</td><td align="center">AD<break/>(n = 152)</td><td align="center">VaD<break/>(n = 192)</td><td align="center" colspan="3">AD <italic>vs </italic>Control</td><td align="center" colspan="3">VaD <italic>vs </italic>control</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td align="center">OR<sup>a</sup></td><td align="center">95% CI<sup>b</sup></td><td align="center">P value</td><td align="center">OR</td><td align="center">95%<break/>CI</td><td align="center">P value</td></tr></thead><tbody><tr><td align="left">Genotype frequency</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;CC</td><td align="center">103 (38.4)</td><td align="center">56 (36.8)</td><td align="center">84 (43.8)</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">&#x02003;CT</td><td align="center">124 (46.3)</td><td align="center">67 (44.1)</td><td align="center">74 (38.5)</td><td align="center">0.994</td><td align="center">0.640 &#x02013; 1.544</td><td align="center">0.978</td><td align="center">0.732</td><td align="center">0.487 &#x02013; 1.100</td><td align="center">0.133</td></tr><tr><td align="left">&#x02003;TT</td><td align="center">41 (15.3)</td><td align="center">29 (20.1)</td><td align="center">34 (17.7)</td><td align="center">1.301</td><td align="center">0.731 &#x02013; 2.315</td><td align="center">0.371</td><td align="center">1.017</td><td align="center">0.594 &#x02013; 1.742</td><td align="center">0.952</td></tr><tr><td align="left">Allele frequency</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;C</td><td align="center">330 (61.6)</td><td align="center">179 (58.9)</td><td align="center">242 (63.0)</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">&#x02003;T</td><td align="center">206 (38.4)</td><td align="center">125 (41.1)</td><td align="center">142 (37.0)</td><td align="center">1.119</td><td align="center">0.839 &#x02013; 1.491</td><td align="center">0.444</td><td align="center">0.940</td><td align="center">0.717 &#x02013; 1.232</td><td align="center">0.654</td></tr></tbody></table><table-wrap-foot><p>Figures in parentheses are percentages</p><p><sup>a</sup>Odds ratio</p><p><sup>b</sup>Confidence interval</p></table-wrap-foot></table-wrap><p>We also investigated the genotype and allele frequencies of <italic>PRNP </italic>1368 in 192 Korean VaD patients to determine whether this polymorphism correlated with VaD. There were no significant differences in genotype and allele frequencies between VaD patients and controls (Table <xref ref-type="table" rid="T2">2</xref>). In addition, analysis of the haplotype frequency was performed in AD patients, VaD patients and controls. Six haplotypes of the 3 <italic>PRNP </italic>polymorphisms were constructed in Koreans. One (ht 5) of these six haplotypes was significantly over-represented in Korean VaD patients (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Haplotype frequency of three PRNP polymorphisms in the normal population, AD patients, and VaD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Haplotypes</td><td align="center">1368</td><td align="center">Codon 129</td><td align="center">Codon 219</td><td align="center" colspan="3">Frequency</td><td align="center" colspan="3">P value</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td align="center">AD</td><td align="center">VaD</td><td align="center">Control</td><td align="center">AD <italic>vs </italic>Control</td><td align="center">VaD <italic>vs </italic>Control</td><td align="center">AD <italic>vs </italic>VaD</td></tr></thead><tbody><tr><td align="center">ht1</td><td align="center">C</td><td align="center">A</td><td align="center">G</td><td align="center">0.5592</td><td align="center">0.5622</td><td align="center">0.5951</td><td align="center">-</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="center">ht2</td><td align="center">T</td><td align="center">A</td><td align="center">G</td><td align="center">0.3618</td><td align="center">0.3623</td><td align="center">0.3450</td><td align="center">0.479</td><td align="center">0.451</td><td align="center">0.996</td></tr><tr><td align="center">ht3</td><td align="center">T</td><td align="center">A</td><td align="center">A</td><td align="center">0.0263</td><td align="center">0.0142</td><td align="center">0.0292</td><td align="center">0.990</td><td align="center">0.167</td><td align="center">0.215</td></tr><tr><td align="center">ht4</td><td align="center">T</td><td align="center">G</td><td align="center">G</td><td align="center">0.0197</td><td align="center">0.0037</td><td align="center">0.0115</td><td align="center">0.280</td><td align="center">0.252</td><td align="center">0.050</td></tr><tr><td align="center">ht5</td><td align="center">C</td><td align="center">A</td><td align="center">A</td><td align="center">0.0164</td><td align="center">0.0352</td><td align="center">0.0109</td><td align="center">0.333</td><td align="center"><bold>0.013</bold></td><td align="center">0.226</td></tr><tr><td align="center">ht6</td><td align="center">C</td><td align="center">G</td><td align="center">G</td><td align="center">0.0066</td><td align="center">0.0224</td><td align="center">0.0083</td><td align="center">1.0</td><td align="center">0.078</td><td align="center">0.197</td></tr></tbody></table></table-wrap></sec><sec><title>Discussion</title><p>In this study, we failed to detect a significant association between the <italic>PRNP </italic>1368 polymorphism and the occurrence of either AD or VaD in the Korean population.</p><p>There is the possibility that the <italic>PRNP </italic>1368 polymorphism is not functional with regard to affecting the level of PrP<sup>C</sup>. Another possibility is that a false negative result was obtained due to statistical powers. Data for AD and VaD patients showed a statistical power of 19.1% and 11.2%, respectively, at the Type I error rate of 0.05 compared with healthy controls. The statistical powers aren't high enough for ensuring that the <italic>PRNP </italic>1368 polymorphism is not relevant to prion replication. However, in the haplotype analysis among 3 <italic>PRNP </italic>polymorphisms, haplotype ht5 was the only haplotype significantly associated with VaD (p = 0.013) (Table <xref ref-type="table" rid="T3">3</xref>) and the genotype frequency of <italic>PRNP </italic>1368 polymorphism in VaD patients was not in HWE. These results suggested some interaction among 3 <italic>PRNP </italic>polymorphisms in the determination of VaD risk and were needed for further evaluation of the association of <italic>PRNP </italic>1368 polymorphism with VaD in other ethnic groups.</p><p>Although the exact function of the prion protein is not fully understood, it might be involved in the development and intensity of oxidative stress and, thereby, contribute to neurodegeneration. Thus, polymorphisms in the coding region of <italic>PRNP </italic>might influence other neurodegenerative disorders in addition to prion diseases. Many studies on a correlation between the <italic>PRNP </italic>codon 129 and AD in various populations have yielded contradictory results [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. This controversial result may be due to the different sample size of the population analyzed, to a difference in frequency of <italic>PRNP </italic>genotypes between different ethnic groups [<xref ref-type="bibr" rid="B29">29</xref>], or even to a difference in age of onset. In our previous studies, we failed to detect a significant association between <italic>PRNP </italic>polymorphism at codons 129/219 and the risk for AD or VaD in the Korean population [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>].</p><p>Recently, there has been growing concern about several polymorphisms outside the ORF of <italic>PRNP</italic>, as there is evidence that levels of <italic>PRNP </italic>expression influence incubation time and the susceptibility to prion diseases. Polymorphisms in the <italic>PRNP </italic>promoter region may be associated with increased susceptibility of prion diseases in cattle and mice [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. These <italic>PRNP </italic>promoter polymorphisms influence the <italic>PRNP </italic>gene expression level [<xref ref-type="bibr" rid="B35">35</xref>]. Overexpression of <italic>PRNP </italic>in transgenic mice led to a decrease in incubation time, whereas <italic>PRNP </italic>knockout mice were resistant to prion disease after infection [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Therefore, we suggest that the polymorphism of <italic>PRNP </italic>1368, located in the promoter region, may influence the expression of the <italic>PRNP </italic>gene; the promoter polymorphisms of <italic>PRNP </italic>might also be associated with other neurodegenerative diseases. In previous studies, several polymorphisms were identified in intronic and upstream regions of human <italic>PRNP</italic>. The single nucleotide polymorphism (SNP) at position -101 (<italic>PRNP </italic>12533) within the regulatory region of <italic>PRNP </italic>was associated with sporadic CJD in the British population [<xref ref-type="bibr" rid="B38">38</xref>], but not in samples derived from Dutch and German populations [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B39">39</xref>].</p><p>Even though these results did not show a relationship between <italic>PRNP </italic>1368 and AD or VaD, it would be useful to assess associations between AD/VaD and other <italic>PRNP </italic>polymorphisms in the promoter region, including the <italic>PRNP </italic>12533 polymorphism.</p></sec><sec><title>Conclusion</title><p><italic>PRNP </italic>1368 polymorphism was not significantly associated with incidence of sporadic AD and VaD in Koreans. However, in the haplotype analysis among 3 <italic>PRNP </italic>polymorphisms, we observed a significant association between haplotype ht5 and VaD. Our report is the first association study of a polymorphism outside the coding region of <italic>PRNP </italic>with AD and VaD.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>BHJ and YSK designed the study. BHJ, KHL, and YJL performed the genotyping. BHJ, YJK, EKC, YHK, YSC, and YSK analyzed the data. BHJ, EKC, and YJK performed statistical analysis. BHJ, YJK, RIC, and YSK wrote the paper. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/32/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2006-311-E00034).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name></person-group><article-title>The genetic epidemiology of neurodegenerative disease</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>1449</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">15931380</pub-id><pub-id pub-id-type="doi">10.1172/JCI24761</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esiri</surname><given-names>MM</given-names></name><name><surname>Carter</surname><given-names>J</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name></person-group><article-title>Prion protein immunoreactivity in brain samples from an unselected autopsy population: findings in 200 consecutive cases</article-title><source>Neuropathol Appl Neurobiol</source><year>2000</year><volume>26</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">10886685</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2990.2000.00239.x</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Carmona</surname><given-names>M</given-names></name><name><surname>Puig</surname><given-names>B</given-names></name><name><surname>Ribera</surname><given-names>R</given-names></name><name><surname>Rey</surname><given-names>MJ</given-names></name><name><surname>Ribalta</surname><given-names>T</given-names></name></person-group><article-title>Prion protein expression in senile plaques in Alzheimer's disease</article-title><source>Acta Neuropathologica</source><year>2001</year><volume>101</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11194941</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kov&#x000e1;cs</surname><given-names>GG</given-names></name><name><surname>Head</surname><given-names>MW</given-names></name><name><surname>Hegyi</surname><given-names>I</given-names></name><name><surname>Bunn</surname><given-names>TJ</given-names></name><name><surname>Flicker</surname><given-names>H</given-names></name><name><surname>Hainfellner</surname><given-names>JA</given-names></name><name><surname>McCardle</surname><given-names>L</given-names></name><name><surname>L&#x000e1;szl&#x000f3;</surname><given-names>L</given-names></name><name><surname>Jarius</surname><given-names>C</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes</article-title><source>Brain Pathol</source><year>2002</year><volume>12</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11770893</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hainfellner</surname><given-names>JA</given-names></name><name><surname>Wanschitz</surname><given-names>J</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name><name><surname>Liberski</surname><given-names>PP</given-names></name><name><surname>Gullotta</surname><given-names>F</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease</article-title><source>Acta Neuropathol</source><year>1998</year><volume>96</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">9705125</pub-id><pub-id pub-id-type="doi">10.1007/s004010050870</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>S</given-names></name></person-group><article-title>Prion disease genetics</article-title><source>Eur J Hum Genet</source><year>2006</year><volume>14</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">16391566</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201544</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Puopolo</surname><given-names>M</given-names></name><name><surname>Ladogana</surname><given-names>A</given-names></name><name><surname>Pocchiari</surname><given-names>M</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Collins</surname><given-names>SJ</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Giulivi</surname><given-names>A</given-names></name><name><surname>Coulthart</surname><given-names>M</given-names></name><name><surname>Delasnerie-Laupretre</surname><given-names>N</given-names></name><name><surname>Brandel</surname><given-names>JP</given-names></name><name><surname>Zerr</surname><given-names>I</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>de Pedro-Cuesta</surname><given-names>J</given-names></name><name><surname>Calero-Lara</surname><given-names>M</given-names></name><name><surname>Glatzel</surname><given-names>M</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Bishop</surname><given-names>M</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Belay</surname><given-names>G</given-names></name><name><surname>Will</surname><given-names>R</given-names></name><name><surname>Mitrova</surname><given-names>E</given-names></name><collab>EUROCJD</collab></person-group><article-title>Genetic prion disease: the EUROCJD experience</article-title><source>Hum Genet</source><year>2005</year><volume>118</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16187142</pub-id><pub-id pub-id-type="doi">10.1007/s00439-005-0020-1</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petraroli</surname><given-names>R</given-names></name><name><surname>Pocchiari</surname><given-names>M</given-names></name></person-group><article-title>Codon 219 polymorphism of PRNP in healthy Caucasians and Creutzfeldt-Jakob disease patients</article-title><source>Am J Hum Genet</source><year>1996</year><volume>58</volume><fpage>888</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">8644754</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Jin</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JI</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Association of sporadic Creutzfeldt-Jakob disease with homozygous genotypes at PRNP codons 129 and 219 in the Korean population</article-title><source>Neurogenetics</source><year>2005</year><volume>6</volume><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">16217673</pub-id><pub-id pub-id-type="doi">10.1007/s10048-005-0016-y</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>MS</given-names></name><name><surname>Dryden</surname><given-names>AJ</given-names></name><name><surname>Hughes</surname><given-names>JT</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease</article-title><source>Nature</source><year>1991</year><volume>352</volume><fpage>340</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">1677164</pub-id><pub-id pub-id-type="doi">10.1038/352340a0</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>S</given-names></name><name><surname>Higuchi</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>RW</given-names></name><name><surname>Tateishi</surname><given-names>J</given-names></name><name><surname>Kitamoto</surname><given-names>T</given-names></name></person-group><article-title>Codon 219 Lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease</article-title><source>Ann Neurol</source><year>1998</year><volume>43</volume><fpage>826</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">9629853</pub-id><pub-id pub-id-type="doi">10.1002/ana.410430618</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Croes</surname><given-names>EA</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Broeck</surname><given-names>M Van den</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease</article-title><source>Ann Neurol</source><year>2003</year><volume>53</volume><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">12601712</pub-id><pub-id pub-id-type="doi">10.1002/ana.10507</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gacia</surname><given-names>M</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Styczy&#x000f1;ska</surname><given-names>M</given-names></name><name><surname>Jakubowska</surname><given-names>K</given-names></name><name><surname>Pep&#x00142;o&#x000f1;ska</surname><given-names>B</given-names></name><name><surname>Chodakowska-Zebrowska</surname><given-names>M</given-names></name><name><surname>Przekop</surname><given-names>I</given-names></name><name><surname>S&#x00142;owik</surname><given-names>A</given-names></name><name><surname>Gola&#x000f1;ska</surname><given-names>E</given-names></name><name><surname>Hu&#x00142;as-Bigoszewska</surname><given-names>K</given-names></name><name><surname>Chlubek</surname><given-names>D</given-names></name><name><surname>Religa</surname><given-names>D</given-names></name><name><surname>Zekanowski</surname><given-names>C</given-names></name><name><surname>Barcikowska</surname><given-names>M</given-names></name></person-group><article-title>Prion protein gene M129 allele is a risk factor for Alzheimer's disease</article-title><source>J Neural Transm</source><year>2006</year><volume>113</volume><fpage>1747</fpage><lpage>1751</lpage><pub-id pub-id-type="pmid">16897605</pub-id><pub-id pub-id-type="doi">10.1007/s00702-006-0540-4</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Golanska</surname><given-names>E</given-names></name><name><surname>Hulas-Bigoszewska</surname><given-names>K</given-names></name><name><surname>Rutkiewicz</surname><given-names>E</given-names></name><name><surname>Styczynska</surname><given-names>M</given-names></name><name><surname>Peplonska</surname><given-names>B</given-names></name><name><surname>Barcikowska</surname><given-names>M</given-names></name><name><surname>Bratosiewicz-Wasik</surname><given-names>J</given-names></name><name><surname>Liberski</surname><given-names>PP</given-names></name></person-group><article-title>Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>313</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">14745079</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Wagenpfeil</surname><given-names>S</given-names></name><name><surname>Vollmert</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Forstl</surname><given-names>H</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group><article-title>Prion protein codon 129 polymorphism and risk of Alzheimer disease</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>364</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">15277640</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casadei</surname><given-names>VM</given-names></name><name><surname>Ferri</surname><given-names>C</given-names></name><name><surname>Calabrese</surname><given-names>E</given-names></name><name><surname>Grimaldi</surname><given-names>LM</given-names></name><name><surname>Franceschi</surname><given-names>M</given-names></name><name><surname>Veglia</surname><given-names>F</given-names></name><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Mariani</surname><given-names>C</given-names></name></person-group><article-title>Prion protein gene polymorphism and Alzheimer's disease: one modulatory trait of cognitive decline?</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2001</year><volume>71</volume><fpage>279</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">11488277</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.71.2.279</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>S&#x000e1;nchez-Guerra</surname><given-names>M</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Alvarez-Arcaya</surname><given-names>A</given-names></name><name><surname>Berciano</surname><given-names>J</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>N</given-names></name><name><surname>Fern&#x000e1;ndez-Viadero</surname><given-names>C</given-names></name></person-group><article-title>Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>593</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">10953203</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Del Bo</surname><given-names>R</given-names></name><name><surname>Scarlato</surname><given-names>M</given-names></name><name><surname>Ghezzi</surname><given-names>S</given-names></name><name><surname>Martinelli-Boneschi</surname><given-names>F</given-names></name><name><surname>Fenoglio</surname><given-names>C</given-names></name><name><surname>Galimberti</surname><given-names>G</given-names></name><name><surname>Galbiati</surname><given-names>S</given-names></name><name><surname>Virgilio</surname><given-names>R</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Ferrarese</surname><given-names>C</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Bresolin</surname><given-names>N</given-names></name><name><surname>Comi</surname><given-names>GP</given-names></name></person-group><article-title>Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis</article-title><source>Neurobiol Aging</source><year>2006</year><volume>27</volume><fpage>770e1</fpage><lpage>770.e5</lpage><pub-id pub-id-type="pmid">16099550</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohkubo</surname><given-names>T</given-names></name><name><surname>Sakasegawa</surname><given-names>Y</given-names></name><name><surname>Asada</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Mizusawa</surname><given-names>H</given-names></name><name><surname>Hachiya</surname><given-names>NS</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name></person-group><article-title>Absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan</article-title><source>Ann Neurol</source><year>2003</year><volume>54</volume><fpage>553</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">14520676</pub-id><pub-id pub-id-type="doi">10.1002/ana.10748</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vollmert</surname><given-names>C</given-names></name><name><surname>Windl</surname><given-names>O</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Rosenberger</surname><given-names>A</given-names></name><name><surname>Zerr</surname><given-names>I</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Bickeb&#x000f6;ller</surname><given-names>H</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><collab>KORA group</collab><name><surname>Kretzschmar</surname><given-names>HA</given-names></name></person-group><article-title>Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>e53</fpage><pub-id pub-id-type="pmid">17047093</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2006.040931</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Mahal</surname><given-names>SP</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>T</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Sporadic&#x02013;but not variant&#x02013;Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1</article-title><source>Am J Hum Genet</source><year>2001</year><volume>69</volume><fpage>1225</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">11704923</pub-id><pub-id pub-id-type="doi">10.1086/324710</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Croes</surname><given-names>EA</given-names></name><name><surname>Alizadeh</surname><given-names>BZ</given-names></name><name><surname>Bertoli-Avella</surname><given-names>AM</given-names></name><name><surname>Rademaker</surname><given-names>T</given-names></name><name><surname>Vergeer-Drop</surname><given-names>J</given-names></name><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Houwing-Duistermaat</surname><given-names>JJ</given-names></name><name><surname>Wientjens</surname><given-names>DP</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name></person-group><article-title>Polymorphisms in the prion protein gene and in the doppel gene increase susceptibility for Creutzfeldt-Jakob disease</article-title><source>Eur J Hum Genet</source><year>2004</year><volume>12</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">14970845</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201161</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>PRNP 1368 polymorphism is not associated with sporadic Creutzfeldt-Jakob disease in the Korean population</article-title><source>Eur J Neurol</source><year>2008</year><volume>15</volume><fpage>846</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">18549395</pub-id><pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02203.x</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Omar</surname><given-names>R</given-names></name><name><surname>Poulter</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name></person-group><article-title>Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes</article-title><source>Ann Neurol</source><year>2006</year><volume>60</volume><fpage>616</fpage><pub-id pub-id-type="pmid">16969862</pub-id><pub-id pub-id-type="doi">10.1002/ana.20931</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></citation></ref><ref id="B26"><citation citation-type="book"><source>American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders</source><year>1994</year><edition>Fourth</edition><publisher-name>(DSM-IV), Washington, DC</publisher-name><fpage>143</fpage><lpage>147</lpage></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>GC</given-names></name><name><surname>Tatemichi</surname><given-names>TK</given-names></name><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Masdeu</surname><given-names>JC</given-names></name><name><surname>Garcia</surname><given-names>JH</given-names></name><name><surname>Amaducci</surname><given-names>L</given-names></name><name><surname>Orgogozo</surname><given-names>JM</given-names></name><name><surname>Brun</surname><given-names>A</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Moody</surname><given-names>DM</given-names></name><name><surname>O'Brien</surname><given-names>MD</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Grafman</surname><given-names>J</given-names></name><name><surname>Drayer</surname><given-names>BP</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Ogata</surname><given-names>J</given-names></name><name><surname>Kokmen</surname><given-names>E</given-names></name><name><surname>Bermejo</surname><given-names>F</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Gorelick</surname><given-names>PB</given-names></name><name><surname>Bick</surname><given-names>KL</given-names></name><name><surname>Pajeau</surname><given-names>AK</given-names></name><name><surname>Bell</surname><given-names>MA</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Culebras</surname><given-names>A</given-names></name><name><surname>Korczyn</surname><given-names>AD</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Scheinberg</surname><given-names>P</given-names></name></person-group><article-title>Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">8094895</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>NJ</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name></person-group><article-title>A new statistical method for haplotype reconstruction from population data</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>978</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">11254454</pub-id><pub-id pub-id-type="doi">10.1086/319501</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Nam</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Jang</surname><given-names>MK</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Lee</surname><given-names>HD</given-names></name><name><surname>Ju</surname><given-names>YR</given-names></name><name><surname>Jo</surname><given-names>SA</given-names></name><name><surname>Park</surname><given-names>KY</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Polymorphisms of the prion protein gene (PRNP) in a Korean population</article-title><source>J Hum Genet</source><year>2004</year><volume>49</volume><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">15148589</pub-id><pub-id pub-id-type="doi">10.1007/s10038-004-0150-7</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Jeong</surname><given-names>YE</given-names></name><name><surname>Hwang</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Ju</surname><given-names>YR</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Polymorphisms at codons 129 and 219 of the prion protein gene (PRNP) are not associated with sporadic Alzheimer's disease in the Korean population</article-title><source>Eur J Neurol</source><year>2007</year><volume>14</volume><fpage>621</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">17539938</pub-id><pub-id pub-id-type="doi">10.1111/j.1468-1331.2007.01786.x</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Na</surname><given-names>HR</given-names></name><name><surname>Bae</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Absence of association between codon 129 and 219 polymorphisms of the prion protein gene and vascular dementia</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>24</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17570906</pub-id><pub-id pub-id-type="doi">10.1159/000103913</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Genotype distribution of the prion protein gene (PRNP) promoter polymorphisms in Korean cattle</article-title><source>Genome</source><year>2006</year><volume>49</volume><fpage>1539</fpage><lpage>1544</lpage><pub-id pub-id-type="pmid">17426768</pub-id><pub-id pub-id-type="doi">10.1139/G06-110</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kashkevich</surname><given-names>K</given-names></name><name><surname>Humeny</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>U</given-names></name><name><surname>Groschup</surname><given-names>MH</given-names></name><name><surname>Nicken</surname><given-names>P</given-names></name><name><surname>Leeb</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>CM</given-names></name><name><surname>Schiebel</surname><given-names>K</given-names></name></person-group><article-title>Functional relevance of DNA polymorphisms within the promoter region of the prion protein gene and their association to BSE infection</article-title><source>FASEB J</source><year>2007</year><volume>21</volume><fpage>1547</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">17255470</pub-id><pub-id pub-id-type="doi">10.1096/fj.06-7522com</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Sohn</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JO</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Kim</surname><given-names>JI</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>IS</given-names></name><name><surname>Joo</surname><given-names>YS</given-names></name><name><surname>Carp</surname><given-names>RI</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Polymorphisms of the prion protein gene (PRNP) in Hanwoo (Bos taurus coreanae) and Holstein cattle</article-title><source>Genes Genet Syst</source><year>2005</year><volume>80</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">16284424</pub-id><pub-id pub-id-type="doi">10.1266/ggs.80.303</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>P</given-names></name><name><surname>Hamann</surname><given-names>H</given-names></name><name><surname>Dr&#x000f6;gem&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Kashkevich</surname><given-names>K</given-names></name><name><surname>Schiebel</surname><given-names>K</given-names></name><name><surname>Leeb</surname><given-names>T</given-names></name></person-group><article-title>Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in bovine spongiform encephalopathy susceptibility</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>37408</fpage><lpage>37414</lpage><pub-id pub-id-type="pmid">16141216</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M506361200</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bueler</surname><given-names>H</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Sailer</surname><given-names>A</given-names></name><name><surname>Greiner</surname><given-names>RA</given-names></name><name><surname>Autenried</surname><given-names>P</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name><name><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Mice devoid of PrP are resistant to scrapie</article-title><source>Cell</source><year>1993</year><volume>73</volume><fpage>1339</fpage><lpage>1347</lpage><pub-id pub-id-type="pmid">8100741</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(93)90360-3</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westaway</surname><given-names>D</given-names></name><name><surname>Mirenda</surname><given-names>CA</given-names></name><name><surname>Foster</surname><given-names>D</given-names></name><name><surname>Zebarjadian</surname><given-names>Y</given-names></name><name><surname>Scott</surname><given-names>M</given-names></name><name><surname>Torchia</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>SL</given-names></name><name><surname>Serban</surname><given-names>H</given-names></name><name><surname>DeArmond</surname><given-names>SJ</given-names></name><name><surname>Ebeling</surname><given-names>C</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name><name><surname>Carlson</surname><given-names>GA</given-names></name></person-group><article-title>Paradoxical shortening of scrapie incubation times by expression of prion protein transgenes derived from long incubation period mice</article-title><source>Neuron</source><year>1991</year><volume>7</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">1676894</pub-id><pub-id pub-id-type="doi">10.1016/0896-6273(91)90074-A</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCormack</surname><given-names>JE</given-names></name><name><surname>Baybutt</surname><given-names>HN</given-names></name><name><surname>Everington</surname><given-names>D</given-names></name><name><surname>Will</surname><given-names>RG</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Manson</surname><given-names>JC</given-names></name></person-group><article-title>PRNP contains both intronic and upstream regulatory regions that may influence susceptibility to Creutzfeldt-Jakob Disease</article-title><source>Gene</source><year>2002</year><volume>288</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">12034503</pub-id><pub-id pub-id-type="doi">10.1016/S0378-1119(02)00466-3</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bratosiewicz-Wasik</surname><given-names>J</given-names></name><name><surname>Liberski</surname><given-names>PP</given-names></name><name><surname>Golanska</surname><given-names>E</given-names></name><name><surname>Jansen</surname><given-names>GH</given-names></name><name><surname>Wasik</surname><given-names>TJ</given-names></name></person-group><article-title>Regulatory sequences of the PRNP gene influence susceptibility to sporadic Creutzfeldt-Jakob disease</article-title><source>Neurosci Lett</source><year>2007</year><volume>411</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">17134829</pub-id><pub-id pub-id-type="doi">10.1016/j.neulet.2006.08.001</pub-id></citation></ref></ref-list></back></article> 